Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview

Bibliography

• Rezzola S, Belleri M, Gariano G, et al. In vitro and ex vivo retina angiogenesis assays. Angiogenesis 2013. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Kimberly Rawlings, ‘FDA Approves New Biologic Treatment for Wet Age-Related Macular Degeneration’, fda.gov. 2006. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/2006/ucm108685.htm
   Google Scholar
• Bevacizumab prescribing information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125085s0168lbl.pdf
   Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9(6):669-76
   PubMed Web of Science ®Google Scholar
• Longo R, Sarmiento R, Fanelli M, et al. Anti-angiogenic therapy: rationale, challenges and clinical studies. Angiogenesis 2002;5:237-56
   PubMedGoogle Scholar
• Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002;29:10-14
   PubMed Web of Science ®Google Scholar
• Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219(4587):983-5
   PubMed Web of Science ®Google Scholar
• Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989;161(2):851-8
   PubMed Web of Science ®Google Scholar
• Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-9
   PubMed Web of Science ®Google Scholar
• Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989;246:1309-12
   PubMed Web of Science ®Google Scholar
• Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 2005;109(3):227-41
   PubMed Web of Science ®Google Scholar
• Parmeggiani F, Romano MR, Costagliola C, et al. Mechanism of inflammation in age-related macular degeneration. Mediators Inflamm 2012;2012:546786
   PubMed Web of Science ®Google Scholar
• Gordon JD, Mesiano S, Zaloudek CJ, Jaffe RB. Vascular endothelial growth factor localization in human ovary and fallopian tubes: possible role in reproductive function and ovarian cyst formation. J Clin Endocrinol Metab 1996;81(1):353-9
   PubMed Web of Science ®Google Scholar
• Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995;1(10):1024-8
   PubMed Web of Science ®Google Scholar
• Gerber HP, McMurtrey A, Kowalski J, et al. VEGF regulates endothelial cell survival by the PI3-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998;273(46):30366-43
   PubMed Web of Science ®Google Scholar
• Benjamin LE, Golijanin D, Itin A, et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;10;103(2):159-65
   PubMed Web of Science ®Google Scholar
• Yuan F, Chen Y, Dellian M, et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 1996;93(25):14765-70
   PubMed Web of Science ®Google Scholar
• Roberts WG, Palade GE. Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res 1997;15;57(4):765-72
   PubMed Web of Science ®Google Scholar
• Monsky WL, Fukumura D, Gohongi T, et al. Augmentation of transvascular transport of macromolecules and nanoparticles in tumor using endothelial growth factor. Cancer Res 1999;59(16):4129-35
   PubMed Web of Science ®Google Scholar
• Stacker SA, Caesar C, Baldwin ME, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001;7(2):186-91
   PubMed Web of Science ®Google Scholar
• Zlokovic BV. Remodeling after stroke. Nat Med 2006;12(4):390-1
   PubMed Web of Science ®Google Scholar
• Infanger M, Faramarzi S, Grosse J, et al. Expression of vascular endothelial growth factor and receptor tyrosine kinases in cardiac ischemia/reperfusion injury. Cardiovasc Pathol 2007;16(5):291-9
   PubMed Web of Science ®Google Scholar
• Rosengart TK, Lee LY, Patel SR, et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999;100(5):468-74
   PubMed Web of Science ®Google Scholar
• Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;15;99(16):1232-9
   PubMed Web of Science ®Google Scholar
• Kamba T, Tam BY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006;290(2):H560-76
   PubMed Web of Science ®Google Scholar
• Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004;165(1):35-52
   PubMed Web of Science ®Google Scholar
• Tziros C, Freedman JE. The many antithrombotic actions of nitric oxide. Curr Drug Targets 2006;7(10):1243-51
   PubMed Web of Science ®Google Scholar
• Bombeli T, Karsan A, Tait JF, Harlan JM. Apoptotic vascular endothelial cells become procoagulant. Blood 1997;89(7):2429-42
   PubMed Web of Science ®Google Scholar
• Russell DA, Abbott CR, Gough MJ. Vascular endothelial growth factor is associated with histological instability of carotid plaques. Br J Surg 2008;95(5):576-81
   PubMed Web of Science ®Google Scholar
• Wong TY, Klein R, Sun C, et al. Age-related macular degeneration and risk of stroke. Ann Intern Med 2006;145(2):98-107
   PubMed Web of Science ®Google Scholar
• Duan Y, Mo J, Klein R, et al. Age-related macular degeneration is associated with incident myocardial infarction among elderly Americans. Ophthalmology 2007;114(4):732-7
   PubMed Web of Science ®Google Scholar
• Wong TY, Liew G, Mitchell P. Clinical update: new treatments for age related macular degeneration in the UK. Lancet 2007;370(9583):204-6
   PubMed Web of Science ®Google Scholar
• Tuñón J, Ruiz-Moreno JM, Martín-Ventura JL, et al. Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration. Surv Ophthalmol 2009;54(3):339-48
   PubMed Web of Science ®Google Scholar
• Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148(1):43-58.e1
   PubMed Web of Science ®Google Scholar
• Holz FG, Amoaku W, Donate J, et al. SUSTAIN Study Group. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN Study. Ophthalmology 2011;118(4):663-71
   PubMed Web of Science ®Google Scholar
• Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119(7):1388-98
   PubMed Web of Science ®Google Scholar
• Chakravarthy U, Harding SP, Rogers CA, et al. IVAN study investigators. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013;12;382(9900):1258-67
   PubMed Web of Science ®Google Scholar
• Semeraro F, Morescalchi F, Parmeggiani F, et al. Systemic adverse drug reactions secondary to anti-VEGF intravitreal injection in patients with neovascular age-related macular degeneration. Curr Vasc Pharmacol 2011;9(5):629-46
   PubMed Web of Science ®Google Scholar
• Costagliola C, Agnifili L, Arcidiacono B, et al. Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration. Expert Opin Biol Ther 2012;12(10):1299-313
   PubMed Web of Science ®Google Scholar
• Stewart MW. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc 2012;87(1):77-88
   PubMed Web of Science ®Google Scholar
• O'Connor CM, Califf RM, Massey EW, et al. Stroke and acute myocardial infarction in the thrombolytic era: clinical correlates and long-term prognosis. J Am Coll Cardiol 1990;16(3):533-40
   PubMed Web of Science ®Google Scholar
• Rose G. Causes of the trends and variations in CHD mortality in different countries. Int J Epidemiol 1989;18(3 Suppl 1):S174-9
   PubMedGoogle Scholar
• Zehetner C, Kirchmair R, Huber S, et al. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol 2013;97(4):454-9
   PubMed Web of Science ®Google Scholar
• Moreira IS, Fernandes PA, Ramos MJ. Vascular endothelial growth factor (VEGF) inhibition-a critical review. Anticancer Agents Med Chem 2007;7(2):223-45
   PubMed Web of Science ®Google Scholar
• Gu X, Yu X, Dai H. Intravitreal injection of Ranibizumab for treatment of age-related macular degeneration: effects on serum VEGF concentration. Curr Eye Res 2013. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M, ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;5;355(14):1432-44
   PubMed Web of Science ®Google Scholar
• Brown DM, Michels M, Kaiser PK, et al. ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009;116(1):57-65; e5
   PubMed Web of Science ®Google Scholar
• Tufail A, Patel PJ, Egan C, et al. ABC Trial Investigators. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ 2010;340:c2459
   PubMed Web of Science ®Google Scholar
• Ueta T, Yanagi Y, Tamaki Y, Yamaguchi T. Cerebrovascular accidents in ranibizumab. Ophthalmology 2009;116(2):362
   PubMed Web of Science ®Google Scholar
• Li J, Zhang H, Sun P, et al. Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients. Int J Ophthalmol 2013;6(2):169-73
   PubMed Web of Science ®Google Scholar
• Kemp A, Preen DB, Morlet N, et al. Myocardial infarction after intravitreal vascular endothelial growth factor inhibitors: a whole population study. Retina 2013;33(5):920-7
   PubMed Web of Science ®Google Scholar
• Shah AR, Del Priore LV. Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements. Br J Ophthalmol 2009;93(8):1027-32
   PubMed Web of Science ®Google Scholar
• Genentech, Inc. (2004). AvastinTM (bevacizumab) for intravenous use [Package insert]. South San Francisco, CA; 2004
   Google Scholar
• Ziemssen F, Zhu Q, Peters S, et al. Tuebingen Bevacizumab Study GroupZiemssen T. Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study. Int Ophthalmol 2009;29(4):213-24
   PubMedGoogle Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1419-31
   PubMed Web of Science ®Google Scholar
• Antoszyk AN, Tuomi L, Chung CY, Singh A; FOCUS Study group. Ranibizumab combined with Verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 2008;145(5):862-74
   PubMed Web of Science ®Google Scholar
• Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 2010;150(3):315-324.e1
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Eldem B, Guymer R, et al. EXCITE Study Group. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 2011;118(5):831-9
   PubMed Web of Science ®Google Scholar
• Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010;94(1):2-13
   PubMed Web of Science ®Google Scholar
• Boyer DS, Heier JS, Brown DM, et al. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology, 2009;116(9):1731-9
   PubMed Web of Science ®Google Scholar
• Available from: www.fda.gov/MedWatch/safety/2007/Lucentis_DHCP_01-24-2007.pdf
   Google Scholar
• Liew G, Mitchell P. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2007;356(7):747-8; author reply 749-50
   PubMed Web of Science ®Google Scholar
• Boyer DS, et al. A safety overview of ranibizumab in patients with wet AMD: ANCHOR, MARINA, PIER, and SAILOR (2008). Presented at the Annual Meeting of the American Academy of Ophthalmology; 8-11 November 2008; Atlanta, Georgia
   Google Scholar
• Ciulla TA, Rosenfeld PJ. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr Opin Ophthalmol 2009;20(3):158-65
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMEA). Ranibizumab (lucentis): summary of productcharacteristics. 2007. Available from: http://ec.europa.eu/enterprise/pharmaceuticals/register/2007/2007012218294/anx-18294-2n.pdf
   Google Scholar
• Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2012;119(6):1175-83
   PubMed Web of Science ®Google Scholar
• European Medical Agency Lucentis Summary of Product Characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/000715/WC500043546.pdf [Accessed 25 May 2012]
   Google Scholar
• Silva R, Axer-Siegel R, Eldem B, et al. SECURE Study Group. The SECURE study: long-termsafety of ranibizumab 0.5 mg in neovascular age-related macular degeneration. Ophthalmology 2013;120(1):130-9
   PubMed Web of Science ®Google Scholar
• LUMINOUS: study to Observe the Effectiveness and Safety of Ranibizumab Through Individualized Patient Treatment and Associated Outcomes. Available from: http://clinicaltrials.gov/show/NCT01318941 [Accessed 22 July 2013]
   Google Scholar
• CATT Research Group. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;19;364(20):1897-908
   PubMed Web of Science ®Google Scholar
• Steinbrook R. The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 2006;355(14):1409-12
   PubMed Web of Science ®Google Scholar
• Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, et al. Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008;246(1):81-7
   PubMed Web of Science ®Google Scholar
• Landa G, Amde W, Doshi V, et al. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration. Ophthalmologica 2009;223(6):370-5
   PubMed Web of Science ®Google Scholar
• Stepien KE, Rosenfeld PJ, Puliafito CA, et al. Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration. Retina 2009;29(8):1067-73
   PubMed Web of Science ®Google Scholar
• Fong DS, Custis P, Howes J, Hsu JW. Intravitreal Bevacizumab and Ranibizumab for age-related macular degeneration: a Multicenter, Retrospective Study. Opthalmology 2010;117(2):298-302
   PubMed Web of Science ®Google Scholar
• Hwang DJ, Kim YW, Woo SJ, Park KH. Comparison of systemic adverse events associated with intravitreal anti-VEGF injection: ranibizumab versus bevacizumab. J Korean Med Sci 2012;27(12):1580-5
   PubMed Web of Science ®Google Scholar
• Biswas P, Sengupta S, Choudhary R, et al. Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration. Indian J Ophthalmol 2011;59(3):191-6
   PubMed Web of Science ®Google Scholar
• Brechner RJ, Rosenfeld PJ, Babish JD, Caplan S. Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file. Am J Ophthalmol 2011;151(5):887-95; e1
   PubMed Web of Science ®Google Scholar
• Curtis LH, Hammill BG, Schulman KA, Cousins SW. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 2010;128(10):1273-9
   PubMed Web of Science ®Google Scholar
• Alexander SL, Linde-Zwirble WT, Werther W, et al. Annual rates of arterial thromboembolic events in medicare neovascular age-related macular degeneration patients. Ophthalmology 2007;114(12):2174-8
   PubMed Web of Science ®Google Scholar
• Nguyen-Khoa BA, Goehring EL Jr, Werther W, et al. Hospitalized cardiovascular diseases in neovascular age-related macular degeneration. Arch Ophthalmol 2008;126(9):1280-6
   PubMed Web of Science ®Google Scholar
• Campbell RJ, Gill SS, Bronskill SE, et al. Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study. BMJ 2012;345:e4203
   PubMed Web of Science ®Google Scholar
• Ahfat FG, Zaidi FH. Bevacizumab vs ranibizumab an appraisal of the evidence from CATT and IVAN. Eye (Lond) 2013;27(3):289-90
   PubMed Web of Science ®Google Scholar
• Krebs I, Schmetterer L, Boltz A, et al. MANTA Research Group. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol 2013;97(3):266-71
   PubMed Web of Science ®Google Scholar
• Kodjikian L, Souied EH, Mimoun G, et al. GEFAL Study Group. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: results from the GEFAL Noninferiority Randomized Trial. Ophthalmology 2013;120(11):2300-9
   PubMed Web of Science ®Google Scholar
• Available from: http://www.clinicaltrials.gov/ct2/show/NCT00559715?term=VIBERA+Study&rank=1
   Google Scholar
• Semeraro F, Morescalchi F, Duse S, et al. Aflibercept in wet AMD: specific role and optimal use. Drug Des Devel Ther 2013;7:711-22
   PubMed Web of Science ®Google Scholar
• Stewart MW, Rosenfeld PJ, Penha FM, et al. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor trap-eye). Retina 2012;32(3):343-457
   Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, et al. VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119(12):2537-48
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 2014;121(1):193-201
   PubMed Web of Science ®Google Scholar
• VEGF Trap-Eye (aflibercept ophthalmic solution) Briefing Document. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DermatologicandOphthalmicDrugsAdvisoryCommittee/UCM259143.pdf [Accessed 4 January 2013]
   Google Scholar
• Beaumont PE, Petocz P, Kang HK. Is there a risk of stroke with aflibercept. Ophthalmology 2014;121(1):e4
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. VEGF inhibition study in ocular neovascularization clinical trial group. Pegaptanib for neovascular age related macular degeneration. N Engl J Med 2004;351(27):2805-16
   PubMed Web of Science ®Google Scholar
• VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group. Chakravarthy U, Adamis AP, Cunningham ET Jr, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006;113(9):1508-e1-25
   PubMed Web of Science ®Google Scholar
• Ko J, Ross J, Awad H, et al. The effects of ZD6474, an inhibitor of VEGF signaling, on cutaneous wound healing in mice. J Surg Res 2005;129(2):251-9
   PubMed Web of Science ®Google Scholar
• van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA 2005;293(12):1509-13
   PubMed Web of Science ®Google Scholar
• Singerman LJ, Masonson H, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol 2008;92(12):1606-11
   PubMed Web of Science ®Google Scholar
• Pegaptanib Sodium Multi-center Study Group. Long-term efficacy and safety profile of pegaptanib sodium for age-related macular degeneration with choroidal neovascularization--evaluation of extended phase II clinical trial. Nihon Ganka Gakkai Zasshi 2011;115(2):122-33
   PubMedGoogle Scholar
• Rinaldi M, Chiosi F, dell'Omo R, et al. Intravitreal pegaptanib sodium (Macugen®) for treatment of diabetic macular oedema: a morphologic and functional study. Br J Clin Pharmacol 2012;74:940-6
   PubMed Web of Science ®Google Scholar
• Rinaldi M, Chiosi F, Dell'Omo R, et al. Intravitreal pegaptanib sodium (Macugen) for treatment of myopic choroidal neovascularization: a morphologic and functional study. Retina 2013;33:397-402
   PubMed Web of Science ®Google Scholar
• Binder S. Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance? Br J Ophthalmol 2012;96(1):1-2
   PubMed Web of Science ®Google Scholar
• Wong TY, Klein R, Sun C, et al. Atherosclerosis risk in communities study. Age-related macular degeneration and risk for stroke. Ann Intern Med 2006;145(2):98-106
   PubMed Web of Science ®Google Scholar
• Ueta T. Safety in Aflibercept versus Ranibizumab. Ophthalmology 2014;121(1):e5
   PubMedGoogle Scholar
• Macugen AMD Study Group. Apte RS, Modi M, Masonson H, et al. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology 2007;114(9):1702-12
   PubMed Web of Science ®Google Scholar
• Jivraj J, Jivraj I, Tennant M, Rudnisky C. Prevalence and impact of depressive symptoms in patients with age-related macular degeneration. Can J Ophthalmol 2013;48(4):269-73
   PubMed Web of Science ®Google Scholar
• Mathew RS, Delbaere K, Lord SR, et al. Depressive symptoms and quality of life in people with age- related macular degeneration. Ophthalmic Physiol Opt 2011;31(4):375-80
   PubMed Web of Science ®Google Scholar
• Kronmal RA, Hart RG, Manolio TA, et al. Aspirin use and incident stroke in the cardiovascular health study. CHS Collaborative Research Group. Stroke 1998;29(5):887-94
   PubMedGoogle Scholar
• Finger RP, Wiedemann P, Blumhagen F, et al. Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - a non-interventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Acta Ophthalmol 2013;91(6):540-6
   PubMed Web of Science ®Google Scholar
• Raftery J, Clegg A, Jones J, et al. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol 2007;91(9):1244-6
   PubMed Web of Science ®Google Scholar
• Swaroop A, Chew EY, Rickman CB, Abecasis GR. Unraveling a multifactorial late-onset disease: from genetic susceptibility to disease mechanisms for age-related macular degeneration. Annu Rev Genomics Hum Genet 2009;10:19-43
   PubMed Web of Science ®Google Scholar
• Kaiser PK, Boyer DS, Cruess AF, et al. DENALI Study Group. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology 2012;119(5):1001-10
   PubMed Web of Science ®Google Scholar
• Dhalla MS, Shah GK, Blinder KJ, et al. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina 2006;26(9):988-93
   PubMed Web of Science ®Google Scholar
• Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007;114(6):1179-85
   PubMed Web of Science ®Google Scholar
• Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Graefes Arch Clin Exp Ophthalmol 2007;245(9):1273-80
   PubMed Web of Science ®Google Scholar
• Hara R, Kawaji T, Inomata Y, et al. Photodynamic therapy alone versus combined with intravitreal bevacizumab for neovascular age-related macular degeneration without polypoidal choroidal vasculopathy in Japanese patients. Graefes Arch Clin Exp Ophthalmol 2010;248(7):931-6
   PubMed Web of Science ®Google Scholar
• Spielberg L, Leys A. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years. Graefes Arch Clin Exp Ophthalmol 2010;248(7):943-56
   PubMed Web of Science ®Google Scholar
• Lim JY, Lee SY, Kim JG, et al. Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study. Acta Ophthalmol 2012;90(1):61-7
   PubMed Web of Science ®Google Scholar
• Larsen M, Schmidt-Erfurth U, Lanzetta P, et al. MONT BLANC Study Group. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration. Twelve-month MONT BLANC study results. Ophthalmology 2012;119(5):992-1000
   PubMed Web of Science ®Google Scholar
• Potter MJ, Claudio CC, Szabo SM. A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study. Br J Ophthalmol 2010;94(2):174-9
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Kohno T, Yamamoto M, et al. Two-year results of reduced-fluence photodynamic therapy combined with intravitreal ranibizumab for typical age-related macular degeneration and polypoidal choroidal vasculopathy. Jpn J Ophthalmol 2013;57(3):283-93
   PubMed Web of Science ®Google Scholar
• Costagliola C, Romano MR, Rinaldi M, et al. Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Br J Ophthalmol 2010;94(2):180-4
   PubMed Web of Science ®Google Scholar
• Becerra EM, Morescalchi F, Gandolfo F, et al. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration. Curr Drug Targets 2011;12(2):149-72
   PubMed Web of Science ®Google Scholar
• Tsuchihashi T, Mori K, Ueyama K, Yoneya S. Five-year results of photodynamic therapy with verteporfin for Japanese patients with neovascular age-related macular degeneration. Clin Ophthalmol 2013;7:615-20
   PubMedGoogle Scholar
• Avery RL. What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned? Br J Ophthalmol 2013. [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar